People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Biotechnology, Pharmaceuticals, Other Health Care, Other, Business Services
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Centrexion Therapeutics Corp | — | Biotechnology | Series C | $202.0M | $35.3M | 2013 |
| Avalo Therapeutics, Inc. | — | Biotechnology | Series D+ | $181.8M | $1.6B | 2016 |
| Diffusion Pharmaceuticals Inc. | — | Pharmaceuticals | Series C | $140.0M | $26.3M | 2014 |
| InspireMD, Inc. | — | Other Health Care | Series C | $117.2M | $248.3M | 2016 |
| Elucida Oncology, Inc. | — | Biotechnology | Series B | $117.1M | $255.6M | 2017 |
| Elicio Therapeutics, Inc. | — | Biotechnology | Series B | $105.3M | $392.9M | 2018 |
| BillMyParents, Inc. | — | Other | Series A | $81.6M | $184.9M | 2011 |
| X4 Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $73.2M | $1.2B | 2015 |
| Alveo Technologies Inc. | — | Biotechnology | Series C | $63.6M | $503.5M | 2016 |
| Premier Alliance Group, Inc. | — | Business Services | Series A | $58.1M | $75.2M | 2014 |
| Aridis Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $56.6M | $63.0M | 2016 |
| X-Vax Technology, Inc. | — | Biotechnology | Series C | $56.6M | $2.3B | 2016 |
| Sapience Therapeutics, Inc. | — | Biotechnology | Series B | $30.8M | $317.9M | 2015 |
| Regenovation, Inc. | — | Biotechnology | Seed | $1.4M | $61.1M | 2015 |
Isaac Blech at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Isaac Blech on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Ruffolo | 5 | 8 |
| Sol J. Barer | 3 | 6 |
| Sol Barer | 3 | 6 |
| Isaac J. Blech | 2 | 3 |
| Isaac A. Blech | 2 | 3 |
| Isaac M. Blech | 2 | 2 |
| Michael Smith | 1 | 20 |
| Arnold Oronsky | 1 | 10 |
| Nicholas Brathwaite | 1 | 9 |
| Michael Berman | 1 | 7 |
| Wesley Clark | 1 | 7 |
| EUGENE A. BAUER | 1 | 7 |
| Aaron Kantoff | 1 | 6 |
| Michael Gilman | 1 | 6 |
| Daniel Geffken | 1 | 6 |
| Arnold L. Oronsky | 1 | 6 |
| MICHAEL J. WARD | 1 | 5 |
| William Kelly | 1 | 5 |
| James Barry | 1 | 5 |
| Michael T. Smith | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.